Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is seeking applications for Exploratory/Developmental Bioengineering Research Grants (EBRG) to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. The grant aims to support innovative bioengineering research that can lead to significant advancements in medical care and research. • The grant is open to various types of applicants, including county governments, city or township governments, state governments, native American tribal organizations, private institutions of higher education, and non-profits. • The grant will support research in areas such as cancer cause and prevention, cancer detection and diagnosis, cancer treatment, and cancer biology. • The application due date is January 7, 2028. • The grant is expected to support around 100 applications, with an expected application size of 0. • The grant is open to electronic submissions only.